Lapaquistat
Alternative Names: Lapaquistat acetate; T 91485; TAK 475Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Takeda
- Class Antihyperlipidaemics; Oxazepines; Piperidines
- Mechanism of Action Squalene synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 28 Mar 2008 Discontinued - Phase-II for Hyperlipidaemia in Japan (PO)
- 28 Mar 2008 Discontinued - Phase-III for Hyperlipidaemia in Europe (PO)
- 28 Mar 2008 Discontinued - Phase-III for Hyperlipidaemia in USA (PO)